BB Biotech AG (BBAGF) Research
Operated by Bellevue Asset Management AG, BB Biotech AG functions as an equity fund primarily concentrating its global investments on publicly listed firms pioneering modern biotechnology, specifically in the fields of medications and diagnostics. Its portfolio is meticulously constructed using a thorough fundamental analysis approach. This Swiss-domiciled fund was established on November 9, 1993.
Market snapshot
- Symbol
- BBAGF
- Price
- $53.60
- Day change
- -1.96%
- Market cap
- $2.5B
- P/E ratio
- -8.70x
- 52-week range
- 33.6454-61.55
- Sector
- Financial Services
- Industry
- Asset Management
- Next earnings
- in 1 month
Peer companies
- AVI Global Trust plc (AVGTF)
- Baillie Gifford US Growth Trust PLC (BLGFF)
- BlackRock World Mining Trust plc (BWMTF)
- The City of London Investment Trust plc (CYLTF)
- The Edinburgh Investment Trust plc (EHITF)
- Henderson European Trust Plc (HNDEF)
- The Monks Investment Trust PLC (MNKIF)
- The European Smaller Companies Trust PLC (TEUUF)
Open BB Biotech AG (BBAGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.